Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Aurinia Pharmaceuticals Inc (AUPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: AUPH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $10
1 Year Target Price $10
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.74% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.17B USD | Price to earnings Ratio 32 | 1Y Target Price 10 |
Price to earnings Ratio 32 | 1Y Target Price 10 | ||
Volume (30-day avg) 6 | Beta 1.16 | 52 Weeks Range 5.20 - 10.67 | Updated Date 06/30/2025 |
52 Weeks Range 5.20 - 10.67 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16.11% | Operating Margin (TTM) 37.43% |
Management Effectiveness
Return on Assets (TTM) 5.2% | Return on Equity (TTM) 11.23% |
Valuation
Trailing PE 32 | Forward PE 15.15 | Enterprise Value 929608083 | Price to Sales(TTM) 4.72 |
Enterprise Value 929608083 | Price to Sales(TTM) 4.72 | ||
Enterprise Value to Revenue 3.76 | Enterprise Value to EBITDA 14.11 | Shares Outstanding 135104000 | Shares Floating 131179522 |
Shares Outstanding 135104000 | Shares Floating 131179522 | ||
Percent Insiders 9.84 | Percent Institutions 47.38 |
Analyst Ratings
Rating 3 | Target Price 10 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aurinia Pharmaceuticals Inc
Company Overview
History and Background
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies to treat autoimmune diseases. Founded in 2006, its significant milestone is the FDA approval of LUPKYNISu00ae for lupus nephritis.
Core Business Areas
- Lupus Nephritis: Focused on developing and commercializing LUPKYNISu00ae (voclosporin) for the treatment of lupus nephritis (LN).
Leadership and Structure
Peter Greenleaf is the President and CEO. The company has a board of directors and operates through various departments including research, development, commercial, and finance.
Top Products and Market Share
Key Offerings
- LUPKYNISu00ae (voclosporin): LUPKYNISu00ae is an oral calcineurin inhibitor approved for the treatment of adult patients with active lupus nephritis. Market share is still developing. Competitors include cyclophosphamide and mycophenolate mofetil, as well as other immunosuppressants.
Market Dynamics
Industry Overview
The autoimmune disease treatment market is growing, driven by increasing prevalence and unmet medical needs. Biopharmaceutical companies are investing heavily in research and development of novel therapies.
Positioning
Aurinia is a key player in the lupus nephritis treatment market with LUPKYNISu00ae. Its competitive advantage lies in its specific mechanism of action and proven efficacy.
Total Addressable Market (TAM)
The Lupus Nephritis Market is estimated at $1.5 Billion and growing, Aurinia's positioning relies on capturing a significant share of this underserved population
Upturn SWOT Analysis
Strengths
- FDA-approved product (LUPKYNIS)
- Strong clinical data supporting LUPKYNIS
- Experienced management team
- Focused on a specific disease area (lupus nephritis)
Weaknesses
- Reliance on a single product (LUPKYNIS)
- Relatively small company compared to larger pharmaceutical players
- High operating expenses related to commercialization
- Requires a partner for global commercialization
Opportunities
- Expansion of LUPKYNIS label to other indications
- Partnerships for global commercialization
- Acquisition by a larger pharmaceutical company
- Development of new therapies for autoimmune diseases
Threats
- Competition from existing and emerging therapies
- Regulatory challenges
- Pricing and reimbursement pressures
- Patent expirations
Competitors and Market Share
Key Competitors
- BMY
- GSK
- HLX
Competitive Landscape
Aurinia's advantage is LUPKYNIS specificity for LN, but faces competition from broader immunosuppressants and larger companies with more resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth depends on revenue from LUPKYNIS sales and partnerships.
Future Projections: Analyst projections depend on LUPKYNIS market penetration and pipeline progress.
Recent Initiatives: Recent initiatives include expanding commercialization efforts and exploring new indications for LUPKYNIS.
Summary
Aurinia Pharmaceuticals is a growing biopharmaceutical company with a key product in LUPKYNIS for lupus nephritis. Its reliance on a single product makes it somewhat vulnerable, but there is potential for future growth. They have an experienced management team, but must deal with competitive pressures. Strategic partnerships and acquisitions could significantly strengthen their position.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, investor presentations, analyst reports, reputable financial websites (e.g., Yahoo Finance, Bloomberg).
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aurinia Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Edmonton, AB, Canada | ||
IPO Launch date 1999-01-26 | President, CEO & Director Mr. Peter S. Greenleaf M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 130 | Website https://www.auriniapharma.com |
Full time employees 130 | Website https://www.auriniapharma.com | ||
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.